Jennifer Hoffman, MD
Infectious Disease · Macon, GANPI 1710153135
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.3% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Medtronic at 53.1% of the total. Reporting peaked in 2023 at $174 and has fallen 62.7% since, to $65 in 2025. That places this record below the midpoint for infectious disease clinicians in GA, where the typical reported total is $922.
Across 10 payments — averaging $32.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$174
- Insmed, Inc.$48
- Viiv Healthcare Company$45
- Melinta Therapeutics, LLC$31
- Gilead$29
Across 10 payments — averaging $2471.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Karyopharm Therapeutics Inc.$13K
- Viiv Healthcare Company$12K
What the payments were for
- Travel & lodging$206%
- Food & beverage$29690%
- Education$124%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $174 |
| Insmed, Inc. | 3 | $48 |
| Viiv Healthcare Company | 2 | $45 |
| Melinta Therapeutics, LLC | 2 | $31 |
| Gilead | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$154
How this compares
$328 in reported general payments places this provider in the 35th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HyqviaIgg/Hyaluronidase,recombinant | 17 | $179,850 |
| CeftriaxoneCeftriaxone Sodium | 16 | $3,110 |
| Vancomycin Hcl | 15 | $1,607 |
| Doxycycline Hyclate | 28 | $704 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $130 |
| Cephalexin | 11 | $57 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Macon
- Jeffrey StephensMacon$356K
- Harold KatnerMacon$21K
- Quyen LuuMacon$12K
- Andrew DoldDacula$1.1M
- Zandraetta Tims-CookAtlanta$848K
- Jose VazquezAugusta$335K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.